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Abstract: A metabolic conversion study on microbes is known as one of the most useful tools to
predict the xenobiotic metabolism of organic compounds in mammalian systems. The microbial
biotransformation of isoxanthohumol (1), a major hop prenylflavanone in beer, has resulted in
the production of three diastereomeric pairs of oxygenated metabolites (2–7). The microbial
metabolites of 1 were formed by epoxidation or hydroxylation of the prenyl group, and HPLC,
NMR, and CD analyses revealed that all of the products were diastereomeric pairs composed of
(2S)- and (2R)- isomers. The structures of these metabolic compounds were elucidated to be (2S,2′′S)-
and (2R,2′′S)-4′-hydroxy-5-methoxy-7,8-(2,2-dimethyl-3-hydroxy-2,3-dihydro-4H-pyrano)-flavanones
(2 and 3), (2S)- and (2R)-7,4′-dihydroxy-5-methoxy-8-(2,3-dihydroxy-3-methylbutyl)-flavanones
(4 and 5) which were new oxygenated derivatives, along with (2R)- and (2S)-4′-hydroxy-5-methoxy-2′′-
(1-hydroxy-1-methylethyl)dihydrofuro[2,3-h]flavanones (6 and 7) on the basis of spectroscopic data.
These results could contribute to understanding the metabolic fates of the major beer prenylflavanone
isoxanthohumol that occur in mammalian system.
Keywords: microbial transformation; hop prenylflavanone; isoxanthohumol
1. Introduction
Isoxanthohumol (1) (5-methoxy-8-prenylnaringenin, C21H22O5) is a well-known prenylated
flavanone which occurs together with the prenylated chalcone xanthohumol in the female
inflorescences (cones) of Humulus lupulus L. (hops) (Cannabaceae), which are added during the beer
brewing process [1,2]. This flavanone has been specifically regarded as a beer prenylflavanone, since it
is the main isomeric product of xanthohumol cyclization formed during hop processing and brewing.
Hops naturally contain only minor quantities of isoxanthohumol compared with those of the most
abundant hop chalcone xanthohumol, whereas beer contains much higher levels of isoxanthohumol
Molecules 2019, 24, 394; doi:10.3390/molecules24030394 www.mdpi.com/journal/molecules
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than xanthohumol [3,4]. Biological and pharmacological properties of isoxanthohumol (1) have been
less characterized than those of xanthohumol, but 1 has shown moderate estrogenic activity [5],
antiproliferative and anticancer activities [6–8], cancer chemoprevention properties [9], and modifying
effects in ontogenetic steroidogenesis [10].
Despite its importance in beer, only a few metabolism studies have been carried out with
isoxanthohumol (1) to identify its metabolic fate in humans. Nikolic and colleagues investigated the
oxidative metabolism of 1 using human liver microsomes in vitro and described several metabolites
on the basis of liquid chromatography-tandem mass spectrometry [11]. Modification on one of the
two terminal methyl groups of the prenyl moiety into the cis- and trans-hydroxymethyl analogues,
respectively, followed by further oxidation to the cis- and trans-aldehydes, and double bond migration
and subsequent hydroxylation to give an exo-methylene with an allylic alcohol was observed.
Derivatives formed by hydroxylation or oxidation on the A- or B-ring, and O-demethylation were also
reported [11]. A recent metabolism study of 1 showed that it was transformed by microorganisms into
derivatives with a dihydrofuran ring or a methoxyglucosyl group [12]. In addition, some metabolic
studies have focused on the conversion or activation of isoxanthohumol into 8-prenylnaringenin,
a potent phytoestrogen [13–15].
Microbial biotransformation studies are regarded as one of the most useful tools to mimic and
predict the xenobiotic metabolism of compounds in mammalian systems. Clark and Hufford have
systematically summarized and reviewed the potential for the microorganisms as tools in the study of
drug metabolisms with a number of specific examples that demonstrated the similarity in microbial and
mammalian metabolism of xenobiotics [16,17]. They noted that microbial systems could offer a reliable,
reproducible alternative to small laboratory animals for preliminary drug metabolism studies to
identify the structural modifications by enzymatic reactions. General techniques and methods utilized
in microbial metabolism studies clearly offer the practical advantages of convenient and inexpensive
maintenance, production of metabolites in high yields and considerable amounts, and curtail the
sacrifice of animals in biomedical research [16–18]. However, despite all the strengths and interesting
parallels enumerated, microbial biotransformation could not ever completely replace the validity of
xenobiotic metabolism studies with animals as well as liver microsomes or perfused livers. This model
is a recently accounted practical tool with high potential for the creation of molecular diversity far
beyond the metabolic changes observed in mammals [18].
We previously reported that microbial biotransformation of hop prenylflavonoids, including
xanthohumol and 8-prenylnaringenin, produced several glucosylated, acyl-glucosylated, and cyclized
metabolites [19,20], while biotransformation of 1 provided a diastereomeric pair of metabolites that
resulted from 7-O-glucosylation on the A-ring via microbial Phase II conjugation reaction [21]. In our
ongoing metabolism study of hop prenylflavonoids, a preparative-scale microbial transformation
of isoxanthohumol (1) by the fungi, Rhizopus oryzae KCTC 6399 and Fusarium oxysporum f.sp. lini
KCTC 16325, afforded three pairs of oxygenated metabolites (2–7) (Figure 1). The production of these
microbially biotransformed metabolites of 1 and their structure elucidation are reported herein.
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were produced as a result of enzymatic activity by the fungi, and not as a consequence of chemical 
or non-metabolic conversion. The ability to biotransform 1 was confirmed on the basis of reversed-
phase (C18) TLC analyses. The Rf values of the three new diasteromeric mixtures (2,3: Rf 0.32, 4,5: 0.42, 
and 6,7: 0.28) were significantly larger than that of 1 (Rf 0.15), which indicated that the fungi produced 
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obtained as a pale yellow amorphous powder. HPLC analyses of the mixture of 2 and 3 revealed that 
each metabolite had the same ultraviolet (UV) spectral data at 190–400 nm and a minor difference of 
retention time (tR) (2: 21.56 min and 3: 22.45 min). Their 1H and 13C-NMR spectra also exhibited nearly 
identical chemical shift and coupling constant values, which suggested that they consisted of a pair 
of diastereomers. HRESIMS of metabolites 2 and 3 exhibited [M+H]+ peaks at m/z 371.1504 and m/z 
371.1482 (calcd for C21H23O6, 371.1495) respectively, which established their molecular formula as 
C21H22O6 and indicated that they were mono-oxygenated metabolites of 1. The UV spectrum of both 
compounds displayed typical absorptions for a flavanone, with a maximum absorption peak at ~287 
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2. Results and Discussion
2.1. Preparation and Microbial Biotransformation of Isoxanthohumol
Preparation of the substrate isoxanthohumol (1) was achieved by both chemical cyclization of
xanthohumol in aqueous alkali solution [4] and enzymatic cyclization using a microbial transformation
method [19]. The isoxanthohumol produced by these methods was a racemic mixture of (2S)- and
(2R)-flavanones, which was confirmed by spectroscopic data analysis showing no absorption in the
CD spectrum and no optical rotation.
A total of forty-one microbial cultures were screened for their ability to metabolize 1 and two
fungi, Rhizopus oryzae KCTC 6399 and Fusarium oxysporum f.sp. lini KCTC 16325, were selected for
further scale-up fermentation studies. For each microbe, separate substrate and culture control studies
were carried out under the same fermentation conditions, which showed that the metabolites were
produced as a result of enzymatic activity by the fungi, and not as a consequence of chemical or
non-metabolic conversion. The ability to biotransform 1 was confirmed on the basis of reversed-phase
(C18) TLC analyses. The Rf values of the three new diasteromeric mixtures (2,3: Rf 0.32, 4,5: 0.42,
and 6,7: 0.28) were significantly larger than that of 1 (Rf 0.15), which indicated that the fungi produced
metabolites with higher polarity.
2.2. Structure Elucidation of Isoxanthohumol Metabolites
Metabolites 2 and 3 of isoxanthohumol were produced by the fungus R. oryzae KCTC 6399 and
obtained as a pale yellow amorphous powder. HPLC analyses of the mixture of 2 and 3 revealed that
each metabolite had the same ultraviolet (UV) spectral data at 190–400 nm and a minor difference
of retention time (tR) (2: 21.56 min and 3: 22.45 min). Their 1H and 13C-NMR spectra also exhibited
nearly identical chemical shift and coupling constant values, which suggested that they consisted of a
pair of diastereomers. HRESIMS of metabolites 2 and 3 exhibited [M + H]+ peaks at m/z 371.1504 and
m/z 371.1482 (calcd for C21H23O6, 371.1495) respectively, which established their molecular formula
as C21H22O6 and indicated that they were mono-oxygenated metabolites of 1. The UV spectrum of
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both compounds displayed typical absorptions for a flavanone, with a maximum absorption peak
at ~287 nm and an inflection at 318 nm, which were similar to those observed for 1. However,
their 1H-NMR spectra showed major differences in the isoprenyl group, which showed two methyl
signals shifted upfield (H-4′′ and H-5′′) at δH 1.31, 1.28 (3H, s) and 1.33, 1.34 (3H, s) as well as a
new oxymethine signal (H-2′′) at δH 3.76 (brt, J = 6.0 Hz) and 3.73 (1H, dd, J = 7.3, 5.8 Hz) in 2 and
3, respectively. These observations suggested that the two sp2 carbons of the isoprenyl group in 1
had been metabolized to oxygenated sp3 carbons. The 13C-NMR data of both compounds showed
resonances for an sp3 oxymethine at δC 69.6 and 69.9 (C-2′′) and an oxygenated sp3 quaternary
carbon at δC 79.9 (C-3′′), and the loss of the olefin signals at δC 124.0 and 131.9 that were observed
in 1. An oxygenated aromatic carbon at δC 161.9 (C-7) in metabolites 2 and 3 was shifted upfield
relative to the corresponding carbon in 1 (δC 164.0). These results indicated that a dihydropyran
ring had been formed by oxidation and subsequent cyclization of the isoprenyl moiety, possibly
going through an epoxide intermediate. Two-dimensional NMR data, including HSQC and HMBC
experiments, supported the presence of a dihydropyran ring. The gem-dimethyl protons H3-4′′ and
H3-5′′ correlated with C-2′′ and C-3′′, and the H2-1′′ methylene protons correlated with C-8 and C-3′′.
Based on these spectroscopic analyses, the planar structure of diastereomeric metabolites 2 and 3 was
assigned as 4′-hydroxy-5-methoxy-7,8-(2,2-dimethyl-3-hydroxy-2,3-dihydro-4H-pyrano)-flavanone.
The absolute configurations of the two asymmetric carbons, C-2 and C-2′′, were established by circular
dichroism [22,23], and the Mosher’s ester method [24,25], respectively. Metabolite 2 displayed positive
and negative Cotton effects at 331 (n→ π* transition) and 288 nm (π→ π* transition), respectively,
which corresponded to a 2S configuration. In contrast, metabolite 3 showed a negative Cotton effect at
334 nm and a positive one at 288 nm which established a 2R configuration (See Supplementary
Materials). The absolute configuration at C-2′′ was determined by the modified Mosher’s
method. Metabolite 3 was converted into the (S)- and (R)-methoxytrifluoromethylphenylacetic acid
(MTPA) esters, 3a and 3b, by treatment with (R)- and (S)-MTPA chloride, respectively. The ∆δ
values (δH = δS − δR, ppm) calculated for the two esters (Figure 2) indicated that C-2′′ had
an S configuration. From these results, unambiguous structures of 2 and 3 were assigned as
(2S,2′′S)- and (2R,2′′S)-4′-hydroxy-5-methoxy-7,8-(2,2-dimethyl-3-hydroxy-2,3-dihydro-4H-pyrano)-
flavanones, respectively.
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Metabolites 4 and 5 of isoxanthohumol were also obtained by the enzymatic activity of R. oryzae
KCTC 6399 and isolated as a pale yellow amorph us pow er. As observed wi h metabolites 2
and 3, HPLC analyses (tR, 4: 11.65 min and 5: 12.56 min) and spectroscopic dat including UV
infrared (IR), 1H- and 13C-NMR spectra indicated that two diastereomeric isomers were produced.
Metabolites 4 and 5 exhibited HRESIMS [M + H]+ peaks at m/z 389.1612 and m/z 389.1600 (calcd for
C21H25O7, 389.1600) respectively, which suggested a molecul r for ula of C21H24O7 corresponding
to dihydroxylat d d rivatives of 1. Th UV spectra of 4 nd 5 displayed characteristic absorptions of
a flavanone moiety at 225, 285 and ~310 nm, which were similar to their substrate 1. H wever,
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the 1H-NMR spectra of 4 and 5 exhibited major differences in the isoprenyl group resonances.
They showed two pairs of methyl signals shifted upfield (H-4′′ and H-5′′) at δH 1.12, 1.15 (3H, s)
and 1.14, 1.16 (3H, s), as well as oxymethine signals (C-2′′) at δH 3.52 (dd, J = 10.0, 2.3 Hz) and 3.55
(dd, J = 10.0, 2.0 Hz), suggesting formation of two hydroxylated sp3 carbons from the olefinic group
of 1. The 13C-NMR spectra of both compounds showed the presence of a hydroxymethine signal
(C-2′′) at δC 80.2 in 4 and δC 80.1 in 5, and an oxygenated quaternary carbon at δC 74.1 (C-3′′) in
both. In addition, 13C-NMR signals of a gem-dimethyl group at δC 25.0 and 26.0, were consistent
with their substitution on an oxygenated carbon. HMBC correlations from H3-4′′ and H3-5′′ to C-2′′
and C-3′′, as well as from H2-1′′ to C-8 and C-2′′, and H-2′′ to C-8 helped to establish the structure
of diastereomers 4 and 5 as 7,4′-dihydroxy-5-methoxy-8-(2,3-dihydroxy-3-methylbutyl)-flavanone.
The absolute configuration of the asymmetric center at C-2 was assigned by CD studies [22,23].
Metabolite 4 displayed positive and negative Cotton effects at 331 (n → π* transition) and 289
nm (π→ π* transition), respectively, corresponding to a 2S configuration, while C-2 in metabolite
5 was established to have a 2R configuration from the opposite Cotton effects at 331 (negative)
and 288 nm (positive). Therefore, the structures of metabolites 4 and 5 were assigned as (2S)- and
(2R)-7,4′-dihydroxy-5-methoxy-8-(2,3-dihydroxy-3-methylbutyl)-flavanones, respectively. Regarding
the determination of absolute configuration at C-2′′, an asymmetric center of oxygenated C-prenyl
side chain in aryl prenyl derivatives, X-ray crystallography has been considered as the most powerful
approach as shown in a case of a prenylated coumarin, meranzin hydrate [26]. Adequate single crystals
of 4 and 5 suitable for X-ray diffraction studies, however, were not available due to the limitations of
their physicochemical properties and limited quantities. Chiroptical tools including electronic circular
dichroism (ECD) were not effectively applicable on account of the strong Cotton effect curves obtained
from (2S)- and (2R)-flavanones [23,27] (See Supplementary Materials). In an effort to determine the
absolute configuration at C-2′′, Mosher’s ester derivatives were prepared, however the results were
ambiguous. The bis-MTPA esters of 4 and 5 provided ∆δ values (δH = δS − δR) that had a non-uniform
distribution of positive and negative signs, which meant that Mosher’s analysis was not valid in this
case [24,25]. Further, chemical synthesis may be necessary to determine absolute configuration of the
chiral carbon C-2′′ at the prenyl moiety.
Metabolites 6 and 7 were also obtained as a pair of diastereomers by microbial transformation
of 1 using F. oxysporum f.sp. lini, which was confirmed by HPLC (tR, 6: 18.63 min and 3: 19.42
min) and NMR experiments. HRESIMS of 6 and 7 showed [M + Na]+ peaks at m/z 393.1307 and
m/z 393.1316 (calcd for C21H23O6Na, 393.1314), respectively, which established their molecular
formula as C21H22O6 which was isomeric with the mono-oxygenated metabolites 2 and 3. However,
several significant differences were observed in the 1H- and 13C-NMR spectra of 6 and 7. Highly
downfield shifted oxymethine proton (δH 4.73, brt, J = 8.8 Hz and 4.74, dd, J = 9.3, 8.0 Hz)
and carbon (δC 92.5) resonances of C-2′′ indicated that a dihydrofuran ring was formed from the
isoprenyl group substituted on the A-ring. The NMR data of 6 and 7 were in good agreement with
those of (2S)-4′-hydroxy-5-methoxy-7,8-[2-(1-hydroxy-1-methylethyl)-2,3-dihydrofurano]flavanone, a
metabolite of xanthohumol by Pichia membranifaciens (ATCC 2254) [28], and (2R)-4′-hydroxy-5-methoxy-
7,8-[2-(1-hydroxy-1-methylethyl)-2,3-dihydrofurano]flavanone, a metabolite of isoxanthohumol by F.
equiseti (AM15) [12]. The structures of compounds 6 and 7 were assigned as 4′-hydroxy-5-methoxy-2′′-
(1-hydroxy-1-methylethyl)dihydrofuro[2,3-h]flavanones, and the absolute configurations of the
asymmetric center at C-2 were identified by CD [22,23]. Metabolite 6 showed negative and positive
Cotton effects at 325 and 289 nm, respectively, corresponding to 2R, while C-2 in metabolite
7 was established to be 2S from the opposite sign Cotton effects at 324 (positive) and 290 nm
(negative). The configuration at C-2′′ in compounds 6 and 7 could not be assigned from the NMR or
CD measurements.
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3. Materials and Methods
3.1. General Experimental Procedures
Optical rotations were recorded with a JASCO DIP 1000 digital polarimeter (JASCO, Tokyo,
Japan). UV spectra were recorded on a JASCO V-530 spectrophotometer (JASCO, Tokyo, Japan),
and CD spectra were recorded on a JASCO J-810 spectrometer (JASCO, Tokyo, Japan). IR spectra
were obtained on a JASCO FT/IR 300-E spectrometer (JASCO, Tokyo, Japan). 1H-, 13C-, HSQC,
and HMBC NMR experiments were recorded using a Varian Unity INOVA 500 spectrometer (Agilent
Technologies, Inc., Santa Clara, CA, USA). HRESIMS were determined on Waters Synapt HDMS
LC/MS mass spectrometer (Waters Corp., Milford, MA, USA). TLC was carried out on Merck silica gel
F254-precoated glass and RP-18 F254S plates (Merck, Darmstadt, Germany). Medium pressure liquid
chromatography (MPLC) was performed using LobarTM C18 column (10 × 240 mm, 40–63 µm, Merck,
Darmstadt, Germany) and silica gel (40–63 µm, Merck). HPLC was performed on a Hewlett-Packard
Agilent 1100 Series (Agilent Technologies, Inc., Santa Clara, CA, USA) HPLC System composed of a
degasser, a binary mixing pump, a column oven and a DAD detector using Waters SunFire™ (Waters
Corp., Milford, MA, USA) (4.6 × 150 mm, 5 µm) and SunFire™ Prep C18 column (10 × 150 mm, 5 µm)
with acetonitrile (solvent A) and water containing 0.1% formic acid (solvent B).
3.2. Chemicals and Ingredients
Isoxanthohumol was prepared by chemical cyclization in aqueous NaOH solution at 0 ◦C as
described by Stevens et al. [4], and also by a microbial transformation method using the fungus R.
oryzae KCTC 6946 as previously reported by Kim and Lee [19]. Isoxanthohumol prepared by both
methods was extracted with EtOAc and then purified by chromatographic methods including silica gel
and reversed-phase C18 MPLC. The spectroscopic data of isoxanthohumol (1) were in good agreement
with data in the literature [1] and its structure was also confirmed by 2D NMR experiments. Optical
rotation and CD measurements revealed that the substrate isoxanthohumol was a racemic mixture
of (2S)- and (2R)-isoxanthohumol. Ingredients for media including D-glucose, peptone, malt extract,
yeast extract, and potato dextrose medium were purchased from Becton, Dickinson and Co. (Sparks,
MD, USA), and sucrose was purchased from Sigma-Aldrich Co. (St Louis, MO, USA).
3.3. Microorganisms and Fermentation
Forty-one microbial strains were obtained from the Korean Collection for Type Cultures (KCTC)
and cultured for preliminary screening. Microorganisms and culture broth composition were described
in the previous literature in detail [20,21].
3.4. Biotransformation Screening Procedure
All of the microbial cultures were grown according to the two-stage procedure [16,17]. In the
screening studies, the actively-growing microbial cultures were inoculated in 100 mL flasks containing
20 mL of media, and incubated with gentle agitation (200 rpm) at 25 ◦C in a temperature-controlled
shaking incubator. Isoxanthohumol (1) (2 mg/0.1 mL in EtOH) was added to each flask 24 h after
inoculation, and further fermented under the same condition for 3 d. Sampling and TLC monitoring
were generally carried out on RP-18 TLC254S with 60% MeOH at 24 h intervals. Two control studies
were performed for identification of metabolites produced by enzymatic transformation. Substrate
controls consisted of 1 and each sterile medium incubated without microorganisms. Culture controls
consisted of fermentation cultures in which the microorganisms were grown without addition of 1.
3.5. Biotransformation of Isoxanthohumol (1) by R. oryzae KCTC 6399
Preparative-scale fermentations were carried out under the same condition with two 1 L flasks
each containing 250 mL of medium and 20 mg of isoxanthohumol (1) for 10 d. The cultures
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were extracted with EtOAc two times and the organic layers were combined and concentrated at
reduced pressure. The EtOAc extract (730 mg) was subjected to silica gel (70–230 mesh, Merck)
column chromatography with a CHCl3–MeOH (9:1) to give three fractions. Fraction 1 (108 mg) was
chromatographed by RP-MPLC (LobarTM, 10 × 240 mm) using 55% MeOH isocratic solvent system to
give a mixture of isoxanthohumol metabolites 2 and 3 (13.2 mg, 15.8% yield). An aliquot of compounds
(7.8 mg) was further chromatographed by HPLC with a gradient solvent system of 20% solvent A to
33% solvent A for 25 min to afford two isomers 2 (1.6 mg, tR 21.56 min) and 3 (2.2 mg, tR 22.45 min).
Fraction 2 (203 mg) was also chromatographed by RP-MPLC (LobarTM, 10 × 240 mm) using aqueous
MeOH solvent (50→ 55%) to give a mixture of metabolites 4 and 5 (7.7 mg, 8.9% yield). A portion of
mixture (4.3 mg) was further purified by HPLC with a gradient solvent system of 20% A to 35% A for
25 min to afford two isomers 4 (1.4 mg, tR 11.65 min) and 5 (1.6 mg, tR 12.56 min).
(2S,2′′S)-4′-Hydroxy-5-methoxy-7,8-(2,2-dimethyl-3-hydroxy-2,3-dihydro-4H-pyrano)-flavanone (2): pale
yellow amorphous powder, [α]D +37.0◦ (c 0.2, MeOH); UV λmax (MeOH) (log ε) 224 (4.35) 285 (4.18),
319 (3.65) nm; CD (MeOH) λext (∆ε): 288 (−13.5), 311 (0.0), 331 (+4.7); IR (KBr) νmax: 3421, 1658, 1608,
1579, 1519, 1485, 1338, 1206, 1133, 1106, 835 cm−1; 1H-NMR (CD3OD, 500 MHz) δ 7.33 (2H, d, J = 8.3 Hz,
H-2′, 6′), 6.82 (2H, d, J = 8.3 Hz, H-3′, 5′), 6.09 (1H, s, H-6), 5.37 (1H, brd, J = 12.5 Hz, H-2), 3.80 (3H, s,
5-OCH3), 3.76 (1H, brt, J = 6.0 Hz, H-2′′), 3.02 (1H, dd, J = 16.5, 13.0 Hz, H-3a), 2.82 (1H, dd, J = 17.0,
5.0 Hz, H-1′′a), 2.70 (1H, dd, J = 16.5, 3.0 Hz, H-3b), 2.55 (1H, dd, J = 17.0, 6.5 Hz, H-1′′b), 1.33 (3H, s,
H-5′′), 1.31 (3H, s, H-4′′); 13C-NMR (CD3OD, 125 MHz) δ 192.7 (C-4), 164.1 (C-8a), 162.0 (C-5), 161.9
(C-7), 159.1 (C-4′), 131.4 (C-1′), 129.0 (C-2′,6′), 116.5 (C-3′,5′), 106.4 (C-4a), 101.9 (C-8), 94.9 (C-6), 80.4
(C-2), 79.9 (C-3′′), 69.6 (C-2′′), 56.3 (5-OCH3), 46.2 (C-3), 26.7 (C-1′′), 25.7 (C-5′′), 22.0 (C-4′′); ESIMS m/z
371 [M + H]+; HRESIMS m/z 371.1504 [M + H]+ (calcd for C21H23O6, 371.1495).
(2R,2′′S)-4′-Hydroxy-5-methoxy-7,8-(2,2-dimethyl-3-hydroxy-2,3-dihydro-4H-pyrano)-flavanone (3): pale
yellow amorphous powder, [α]D +66.4◦ (c 0.2, MeOH); UV λmax (MeOH) (log ε) 224 (4.47), 288 (4.30),
318 (3.77) nm; CD (MeOH) λext (∆ε): 288 (+16.4), 313 (0.0), 334 (−5.4); IR (KBr) νmax: 3421, 1658, 1608,
1578, 1519, 1485, 1337, 1206, 1133, 1106, 835 cm−1; 1H-NMR (CD3OD, 500 MHz) δ 7.32 (2H, d, J = 8.5 Hz,
H-2′, 6′), 6.82 (2H, d, J = 8.5 Hz, H-3′, 5′), 6.08 (1H, s, H-6), 5.36 (1H, dd, J = 13.0, 2.5 Hz, H-2), 3.79
(3H, s, 5-OCH3), 3.73 (1H, dd, J = 7.3, 5.8 Hz, H-2′′), 3.00 (1H, dd, J = 16.5, 13.0 Hz, H-3a), 2.83 (1H, dd,
J = 17.0, 5.5 Hz, H-1′′a), 2.69 (1H, dd, J = 16.5, 3.0 Hz, H-3b), 2.50 (1H, dd, J = 17.0, 7.0 Hz, H-1′′b), 1.34
(3H, s, H-5′′), 1.28 (3H, s, H-4′′); 13C-NMR (CD3OD, 125 MHz) δ 192.7 (C-4), 163.9 (C-8a), 162.0 (C-5),
161.9 (C-7), 159.1 (C-4′), 131.4 (C-1′), 129.0 (C-2′′,6′), 116.5 (C-3′,5′), 106.4 (C-4a), 102.2 (C-8), 94.9 (C-6),
80.3 (C-2), 79.9 (C-3′′), 69.9 (C-2′′), 56.3 (5-OCH3), 46.2 (C-3), 26.7 (C-1′′), 25.9 (C-5′′), 21.3 (C-4′′); ESIMS
m/z 371 [M + H]+; HRESIMS m/z 371.1482 [M + H]+ (calcd for C21H23O6, 371.1495).
(2S)-7,4′-Dihydroxy-5-methoxy-8-(2,3-dihydroxy-3-methylbutyl)-flavanone (4): pale yellow amorphous
powder, [α]D −31.7◦ (c 0.2, MeOH); UV λmax (MeOH) (log ε): 225 (4.42), 285 (4.17), 310 (3.73) nm; CD
(MeOH) λext (∆ε): 289 (−9.1), 313 (0.0), 331 (+4.0); IR (KBr) νmax: 3424, 1600, 1515, 1463, 1351, 1280,
1150, 1099, 828 cm−1; 1H-NMR (CD3OD, 500 MHz) δ 7.34 (2H, d, J = 8.3 Hz, H-2′, 6′), 6.81 (2H, d,
J = 8.3 Hz, H-3′, 5′), 6.16 (1H, s, H-6), 5.33 (1H, brd, J = 13.5 Hz, H-2), 3.81 (3H, s, 5-OCH3), 3.52 (1H,
dd, J = 10.0, 2.3 Hz, H-2′′), 3.00 (1H, dd, J = 16.8, 13.5 Hz, H-3a), 2.93 (1H, brd, J = 14.0 Hz, H-1′′a),
2.69 (1H, brd, J = 16.8 Hz, H-3b), 2.62 (1H, dd, J = 14.0, 10.0 Hz, H-1′′b), 1.14 (3H, s, H-5′′), 1.12 (3H, s,
H-4′′); 13C-NMR (CD3OD, 125 MHz) δ 192.9 (C-4), 165.5 (C-7), 164.2 (C-8a), 162.5 (C-5), 159.0 (C-4′),
131.5 (C-1′), 129.0 (C-2′,6′), 116.4 (C-3′,5′), 108.5 (C-8), 105.9 (C-4a), 94.6 (C-6), 80.4 (C-2), 80.2 (C-2′′),
74.1 (C-3′′), 56.1 (5-OCH3), 46.3 (C-3), 26.6 (C-1′′), 26.0 (C-4′′), 25.0 (C-5′′); ESIMS m/z 389 [M + H]+;
HRESIMS m/z 389.1612 [M + H]+ (calcd for C21H25O7, 389.1600).
(2R)-7,4′-Dihydroxy-5-methoxy-8-(2,3-dihydroxy-3-methylbutyl)-flavanones (5): pale yellow amorphous
powder, [α]D −53.0◦ (c 0.2, MeOH); UV λmax (MeOH) (log ε): 225 (4.30), 285 (4.08), 318 (3.65) nm; CD
(MeOH) λext (∆ε): 288 (+10.8), 311 (0.0), 331 (−3.8); IR (KBr) νmax: 3422, 2975, 1599, 1514, 1463, 1349,
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1281, 1210, 1150, 1101, 829 cm−1; 1H-NMR (CD3OD, 500 MHz) δ 7.34 (2H, d, J = 8.5 Hz, H-2′, 6′), 6.81
(2H, d, J = 8.5 Hz, H-3′, 5′), 6.17 (1H, s, H-6), 5.34 (1H, dd, J = 13.0, 2.5 Hz, H-2), 3.82 (3H, s, 5-OCH3),
3.55 (1H, dd, J = 10.0, 2.0 Hz, H-2′′), 2.98 (1H, dd, J = 16.5, 13.0 Hz, H-3a), 2.95 (1H, dd, J = 14.0, 2.5 Hz,
H-1′′a), 2.70 (1H, dd, J = 16.5, 3.0 Hz, H-3b), 2.61(1H, dd, J = 14.0, 10.0 Hz, H-1′′b), 1.16 (3H, s, H-5′′),
1.15 (3H, s, H-4′′); 13C-NMR (CD3OD, 125 MHz) δ 192.9 (C-4), 165.5 (C-7), 164.0 (C-8a), 162.6 (C-5),
159.0 (C-4′), 131.6 (C-1′), 128.9 (C-2′,6′), 116.4 (C-3′,5′), 108.6 (C-8), 105.8 (C-4a), 94.7 (C-6), 80.5 (C-2),
80.1 (C-2′′), 74.1 (C-3′′), 56.1 (5-OCH3), 46.4 (C-3), 26.7 (C-1′′), 26.0 (C-4′′), 25.0 (C-5′′); ESIMS m/z 389
[M + H]+; HRESIMS m/z 389.1600 [M + H]+ (calcd for C21H25O7, 389.1600).
3.6. Biotransformation of 1 by F. oxysporum f.sp. lini KCTC 16325
Scale-up fermentations were carried out under the same condition with two 1 L Erlenmeyer flasks
each containing 250 mL medium and 25 mg isoxanthohumol (1) for 5 d. Production of a metabolite
was monitored by reversed-phase C18 TLC (MeOH 70%). The red-colored cultures were extracted
with EtOAc two times and the organic layers were combined and concentrated in vacuo. The EtOAc
extract (280 mg) was subjected to silica gel (70–230 mesh, Merck) column chromatography with
n-hexane-EtOAc (2:1) mixture to give three fractions. Fraction 2 (89 mg) containing a metabolite was
chromatographed with MPLC (LobarTM, 10 × 240 mm) using MeOH 45% isocratic solvent system
to afford isoxanthohumol as a mixture of metabolites 6 and 7 (18 mg, 34.3% yield). An aliquot of
compound mixture (3.4 mg) was further chromatographed by HPLC with a gradient solvent system of
20% A to 35% A for 25 min to afford two isomers 6 (1.1 mg, tR 18.63 min) and 7 (1.1 mg, tR 19.42 min).
3.7. Determination of Absolute Configuration by Modified Mosher’s Method
Compound 3 (1.0 mg in 0.2 mL pyridine) was treated with 15 µL (20.3 mg) of
(R)-(−)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (MTPA-chloride), and stirred overnight
at room temperature under nitrogen gas. The reaction mixture was evaporated in vacuo, and
chromatographed by HPLC using a SunFire™ Prep C18 (10 × 150 mm, Waters) with a gradient solvent
MeCN–H2O (70:30→ 90:10) at 3 mL/min for 20 min, afforded the (S)-Mosher ester derivative 3a (tR
17.30, 0.9 mg). The derivative of (R)-Mosher ester 3b (tR 17.49, 1.0 mg) was prepared by reaction of 3
(1.0 mg) with 15 µL of (S)-(−)-MTPA-chloride reagent under the same condition as described above.
3a: 1H-NMR (CDCl3, 500 MHz) δ 6.03 (1H, s, H-6), 5.44 (1H, dd, J = 12.6, 3.0 Hz, H-2), 5.16 (1H,
dd, J = 6.0, 5.4 Hz, H-2′′), 3.86 (3H, s, 5-OCH3), 2.99 (1H, dd, J = 17.4, 5.4 Hz, H-1′′), 2.93 (1H, dd,
J = 16.2, 12.6 Hz, H-3), 2.83 (1H, dd, J = 16.2, 3.0 Hz, H-3), 2.65 (1H, dd, J = 17.4, 6.0 Hz, H-1′′), 1.36 (3H,
s, H-5′′), 1.32 (3H, s, H-4′′). 3b: 1H-NMR (CDCl3, 500 MHz) δ 6.06 (1H, s, H-6), 5.46 (1H, dd, J = 12.6,
3.0 Hz, H-2), 5.16 (1H, dd, J = 6.0, 5.4 Hz, H-2′′), 3.87 (3H, s, 5-OCH3), 3.00 (1H, dd, J = 17.4, 5.4 Hz,
H-1′′), 2.95 (1H, dd, J = 16.2, 12.6 Hz, H-3), 2.87 (1H, J = 16.2, 3.0 Hz, H-3), 2.80 (1H, dd, J = 17.4, 5.4 Hz,
H-1′′), 1.31 (3H, s, H-5′′), 1.27 (3H, s, H-4′′).
4. Conclusions
Microbial transformation studies of isoxanthohumol (1) resulted in the production of three
oxygenated pairs of metabolites (2–7). These include two novel metabolite pairs possessing a
dihydropyran (2,3) and a dihydroxymethylbutane (4,5) substituted flavanone core structure. It was
widely reported that cyclization at the prenyl side chain resulted in forming a five-membered furan or a
six-membered pyran heterocycle attached to the A-ring in prenylated flavanones [29,30]. The formation
of dihydroxymethylbutyl group has frequently occurred by dihydroxylation on the double bond of
the prenyl group substituted to the A ring in biotransformation of prenylated flavanones [29]. These
transformation and derivatization have been commonly encountered in natural products [31], and the
presence of cyclized and dihydroxylated derivatives of the prenyl substituent has been revealed in the
bark of the Amazonian tree Brosimum acutifolium, a rich source of 8-prenylated flavonoids [32].
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Unlike the microbial metabolites 2–7, the regioselectively mono-hydroxylated prenyl side chain
metabolites of isoxanthohumol, namely cis- and trans-prenyl alcohols, were previously identified as
the most abundant oxidation metabolites of isoxanthohumol during in vitro metabolism studies using
human liver microsomes, which was catalyzed by hepatic cytochrome P450 enzymes [11,33]. However,
knowledge of the in vitro microbial metabolic conversions of isoxanthohumol may contribute to the
detection and identification of the metabolic products of isoxanthohumol that occur in mammalian
systems. Conjugation reactions including sulfation and glucuronidation are involved in the major
metabolic pathways of polyphenols in mammals, which metabolize polyphenols into very hydrophilic
conjugates [34,35]. It was previously proved that microbial aryl sulfotransferase was capable of
producing Phase II metabolites of flavonoids, rather close to the mammalian enzyme [35]. Considering
that isoxanthohumol is a significant component of beer and that beer is consumed by a large number
of people world-wide, these findings could have potential health and nutritional implications.
Supplementary Materials: The following are available online, Figures S1–S18: 1D, 2D-NMR spectra of
isoxanthohumol (1) and metabolites 2–7, Scheme S1: HPLC Profiles of oxygenated metabolites (2–7) of
isoxanthohumol (1), Figure S19: High resolution ESIMS data of metabolites 2–7, Figure S20: Circular dichroism
(CD) profiles of metabolites 2–7.
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